https://www.selleckchem.com/pr....oducts/atuveciclib-b
and prognostic markers and as therapeutic targets to avoid graft rejection in patients undergoing kidney transplantation. Our results suggest the importance of the IRF/STAT1 pathways in humoral kidney rejection. NK cells and monocytes in graft damage have an essential role during rejection, and imatinib improves KT outcomes. Our results will have to be validated for the potential use of overexpressed genes as rejection biomarkers that can be used as diagnostic and prognostic markers and as therapeutic targets to avoid gr
Like
Comment
Share
